You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Ultra-High Density Ion Propulsion From Ionic Liquids

    SBC: BUSEK CO., INC.            Topic: AF11BT10

    ABSTRACT: Busek Co. Inc. and Massachusetts Institute of Technology (MIT) propose to explore the physical limits of ionic liquid propulsion via development of new theory to explain effects of close packing emission density and to predict performance limits. The research is motivated by observations and tests demonstrating that emission from 2-dimensional porous surfaces yields order of magnitude g ...

    STTR Phase II 2014 Department of DefenseAir Force
  2. Optical Remote Detection of Low Level Earth Surface Vibrations

    SBC: SPECTRAL SCIENCES INC            Topic: AF12BT02

    ABSTRACT: Underground facilities can be used by rogue governments to conceal command-and-control and to manufacture weapons of mass destruction, and are an increasingly important operational challenge to U.S. military forces. Our objective is to determine improved methods of detection essential to address this critical intelligence need. Activity below the ground causes seismic surface waves th ...

    STTR Phase II 2014 Department of DefenseAir Force
  3. New learning technologies for exploitation of layered sensor data

    SBC: LONGSHORTWAY INC.            Topic: AF12BT14

    ABSTRACT: LongShortWay Inc, Boston University, and Applied Communication Sciences propose to develop a dynamic multi-sensor learning system that can adaptively detect target types and activities and schedule sensors to optimize the detection rate BENEFIT: Improved detection rate, increase field of view

    STTR Phase II 2014 Department of DefenseAir Force
  4. Development of an Innovative System for Cryodeposit Mitigation and Redmediation

    SBC: PHYSICAL SCIENCES INC.            Topic: AF12BT10

    ABSTRACT: Physical Sciences Inc. (PSI) and the University of Tennessee Space Institute (UTSI) will develop an innovative system to measure and control the cryodeposit layer thickness that develops on cold (~20 K) surfaces in cryogenic radiometric calibration chambers. Currently removing the cryo-layer involves a lengthy process that warms the entire cryo-system to desorb the cryo-layer that incr ...

    STTR Phase II 2014 Department of DefenseAir Force
  5. Transdermal Naltrexone for Opiate Addiction and Alcoholism

    SBC: ALLTRANZ, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever, heroin, and alcohol addiction. Naltrexone (NTX), an opioid antagonist, is currently used in oral tablet form to help maintain opio ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Cancer is the second leading cause of death after heart disease in the US Chemotherapy is a mainstay of treatment after surgical removal of tumors but the balance of clinical benefit versus disabling or life threatening side effects is often uncertain Genotyping of cancers to identify mutated oncogenes has enabled an era of targeted therapy Drugs targeting ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Coils for Human Whole Body Imaging at 7T

    SBC: LIFE SERVICES L.L.C.            Topic: NIBIB

    DESCRIPTION provided by applicant For this Phase II STTR proposal the investigators plan to develop and commercialize the radiofrequency RF coil technology to make T body MRI possible and to translate this new technology to vastly improve T clinical MRI as well In the Phase I project leading to this proposal all specific aims were accomplished to demonstrate the feasibility of safely an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Brain penetrant Hsp90 inhibitors for Alzheimer's disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION provided by applicant Neurodegeneration in Alzheimerandapos s disease AD may result from deposition of A as plaques in brain tissue However less effort has been made to elucidate the role of tau containing neurofibrillary tangles NFTs in AD Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neu ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Extending Genome-Phenome Analysis

    SBC: SimulConsult, Inc.            Topic: 172

    DESCRIPTION provided by applicant The declining cost of whole exome sequencing WES is nearing the point at which the spread of WES into clinical practice will be limited largely by the cost of interpreting the results and comparing them to the patientandapos s clinical findings This project builds on our demonstrated capability to reduce this interpretation cost by pairing our diagnostic sof ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government